Following a successful research collaboration, Institut Curie sets a new standard in cancer care with the introduction of Ibex’s AI-powered tools to support pathologists diagnosing cancer.

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, and Institut Curie, France’s globally renowned cancer center, today announced the introduction of Ibex’s AI solution in routine clinical practice. Pathologists at Institut Curie are now using Ibex’s AI tools when diagnosing prostate cancer to enhance accuracy, efficiency and improve patient outcomes; and plan to expand to a series of other Ibex applications in the coming months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121364639/en/

(Photo: Business Wire)

“We’re excited to now use Ibex’s AI technology in routine practice, further building upon our impressive research partnership. It’s a team success between the Pathology team, the IT department, the data protection officer and the Information systems security managers” says Professor Anne Vincent-Salomon, head of the pathology department at Institut Curie, Professor at the University Paris-Sciences et Lettres. “We realize the vital role that accurate diagnostics play in selecting optimal treatment paths, and we’re committed to providing our pathologists with the top-tier technology and tools to ensure every patient receives the highest quality care.”

Institut Curie continues their leadership in digital pathology adoption by implementing Ibex via their Sectra Digital Pathology Solution, providing an integrated workflow for pathologists to access Ibex's AI findings when reviewing cases. They are among the first academic laboratories in the world to utilize this recently released solution that ensures seamless diagnostic workflows. “The implementation of this tool in our department will allow our teams to save time, make our results more reliable, target areas of interest and improve the accuracy of our diagnoses," says Professor Yves Allory, head of the pathology department at the Institut Curie, Saint-Cloud site, Professor at the University Versailles Saint Quentin.

This deployment marks the latest chapter in the ongoing collaboration between the two organizations, which has already yielded groundbreaking advancements in AI-driven cancer diagnostics, including the validation of the Ibex Breast solution published in Nature's npj Breast Cancer.

“We are honored to see our AI platform deployed in routine practice at such a prestigious institution as Institut Curie,” said Joseph Mossel, CEO of Ibex Medical Analytics. “As one of the world’s leading medical and research centers, Institut Curie remains at the forefront of transforming cancer care. This rollout underscores our commitment to making computational pathology a global reality and highlights the transformative potential of AI to reshape the future of cancer care.”

About Ibex Medical Analytics

Ibex Medical Analytics is transforming cancer diagnostics with world-leading clinical grade AI-powered solutions for pathology. Empowering physicians and supporting pathologists, Ibex is on a mission to provide accurate, timely and personalized cancer diagnosis for every patient. Ibex is the first and most widely deployed AI-powered platform in pathology. Pathologists worldwide use Ibex as part of their everyday routine to improve the accuracy of cancer diagnosis, implement comprehensive quality control measures, reduce turnaround times, and boost productivity with more efficient workflows.

The Ibex suite includes solutions which are for Research Use Only (RUO) in the United States and not cleared by the FDA. Multiple solutions are CE marked (IVDD and IVDR) and registered with the UK MHRA. For more information, including indication for use and regulatory approval in other countries, contact Ibex Medical Analytics.

About Institut Curie

Institut Curie, France's leading cancer center, combines an internationally renowned research center with a state-of-the-art hospital complex that treats all cancers, including the rarest. Founded in 1909 by Marie Curie, Institut Curie brings together more than 3,800 researchers, doctors and caregivers on 3 sites (Paris, Saint-Cloud and Orsay) around its 3 missions: care, research and teaching. As a foundation recognized as being of public utility authorized to receive donations and legacies, Institut Curie can, thanks to the support of its donors, accelerate discoveries and thus improve treatments and the quality of life of patients.

For more information: curie.fr, Twitter, Facebook, LinkedIn, Instagram

View source version on businesswire.com: https://www.businesswire.com/news/home/20241121364639/en/